Evidence map›Paper›PMID 32586940›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.

Sophie J Cowman, Daniel G Fuja, Xian-De Liu, Rebecca S Slack Tidwell, Neelima Kandula, Deepika Sirohi, Archana M Agarwal, Lyska L Emerson, Sheryl R Tripp, Jeffrey S Mohlman and 17 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 1 country.

Sophie J CowmanUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-0257-2227
Daniel G FujaUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-9351-7580
Xian-De LiuU.T. M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9639-0458
Rebecca S Slack TidwellU.T. M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3041-8582
Neelima KandulaUniversity of Utah, Salt Lake City, Utah.
Deepika SirohiUniversity of Utah, Salt Lake City, Utah.
Archana M AgarwalUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0003-1076-0428
Lyska L EmersonHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-2367-6578
Sheryl R TrippARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah.
Jeffrey S MohlmanUniversity of Utah, Salt Lake City, Utah.
Miekan StonhillUniversity of Utah, Salt Lake City, Utah.
Guillermina GarciaSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Christopher J ConleyHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Adam A OlaldeSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.ORCID 0000-0002-4107-2479
Timothy SargisSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Adela Ramirez-TorresSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Jose A KaramU.T. M.D. Anderson Cancer Center, Houston, Texas.
Christopher G WoodU.T. M.D. Anderson Cancer Center, Houston, Texas.
Kanishka SircarU.T. M.D. Anderson Cancer Center, Houston, Texas.
Pheroze TamboliU.T. M.D. Anderson Cancer Center, Houston, Texas.
Kenneth BoucherHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-2833-0127
Benjamin MaughanHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Benjamin T SpikeHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Thai H HoMayo Clinic, Scottsdale, Arizona.ORCID 0000-0003-0023-2939
Neeraj AgarwalHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-1076-0428
Eric JonaschU.T. M.D. Anderson Cancer Center, Houston, Texas.
Mei Yee KohUniversity of Utah, Salt Lake City, Utah. mei.koh@utah.edu.ORCID 0000-0002-3241-7316
University of Utah · USThe University of Texas MD Anderson Cancer Center · USDiscovery Institute · USARUP Laboratories (United States) · USMayo Clinic in Arizona · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Deciphering the interplay between H3K36 and DNA methylation in renal cancerR01CA224917 · NCI · MAYO CLINIC ROCHESTER · PI HO, THAI HUU, ROBERTSON, KEITH D · 2018 to 2022
$2.9M
The targeting of the HIF switch in kidney cancerR01CA181106 · NCI · UNIVERSITY OF UTAH · PI KOH, MEI YEE · 2014 to 2017
$2.0M
A novel approach for the selective inhibition of HIF-2a in kidney cancerR01CA217905 · NCI · UNIVERSITY OF UTAH · PI KOH, MEI YEE · 2017 to 2021
$1.7M
NCATS NIH HHS UL1 TR002538NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA030199NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA181106NCI NIH HHS R01 CA217905NCI NIH HHS R01 CA224917
6 · The paper itself

Abstract

purposeClear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel-Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based studies, supports a tumor promoting role for HIF-2α, and a tumor suppressor role for HIF-1α. However, few studies have comprehensively examined the clinical relevance of this paradigm. Furthermore, the hypoxia-associated factor (HAF), which regulates the HIFs, has not been comprehensively evaluated in ccRCC. EXPERIMENTAL

designTo assess the involvement of HAF/HIFs in ccRCC, we analyzed their relationship to tumor grade/stage/outcome using tissue from 380 patients, and validated these associations using tissue from 72 additional patients and a further 57 patients treated with antiangiogenic therapy for associations with response. Further characterization was performed using single-cell mRNA sequencing (scRNA-seq), RNA-

resultsHIF-1α was primarily expressed in tumor-associated macrophages (TAMs), whereas HIF-2α and HAF were expressed primarily in tumor cells. TAM-associated HIF-1α was significantly associated with high tumor grade and increased metastasis and was independently associated with decreased overall survival. Furthermore, elevated TAM HIF-1α was significantly associated with resistance to antiangiogenic therapy. In contrast, high HAF or HIF-2α were associated with low grade, decreased metastasis, and increased overall survival. scRNA-seq, RNA-ISH, and Western blotting confirmed the expression of HIF-1α in M2-polarized CD163-expressing TAMs.

conclusionsThese findings highlight a potential role of TAM HIF-1α in ccRCC progression and support the reevaluation of HIF-1α as a therapeutic target and marker of disease progression.

Indexed as

AdultAgedAged, 80 and overBasic Helix-Loop-Helix ProteinsBiomarkers, TumorCarcinoma, Renal CellCell Line, TumorChemotherapy, AdjuvantDisease ProgressionEndothelial PAS Domain-Containing Protein 1FemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansHypoxia-Inducible Factor 1, alpha SubunitKidney NeoplasmsBasic Helix-Loop-Helix ProteinsBiomarkers, TumorEndothelial PAS Domain-Containing Protein 1HIF1A protein, humanHypoxia-Inducible Factor 1, alpha Subunit

Identifiers

PMID32586940
PMCPMC7968518
OpenAlexW3037831638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.